Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PRNP | P04156 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6792213 | 0.89 | CRHR1 (0.44) | GAAMAPTKDM4EPKMCRHR1 | |
| SCHEMBL6797656 | 0.87 | HPGD (0.47) | GAAMAPTKDM4EPKMCRHR1 | |
| SCHEMBL6799327 | 0.87 | MEN1 (0.41) | GAAMAPTKDM4EPKMCRHR1 | |
| SCHEMBL5844564 | 0.86 | MAPT (0.56) | GAAMAPTKDM4EPKMCRHR1 | |
| SCHEMBL7592652 | 0.83 | GAA (0.51) | GAAMAPTKDM4EPKMCRHR1 | |
| SCHEMBL5844403 | 0.80 | HPGD (0.44) | GAAMAPTKDM4EHSD17B10HPGD | |
| SCHEMBL5844195 | 0.78 | CRHR1 (0.49) | GAACRHR1LMNA | |
| SCHEMBL5845758 | 0.77 | CRHR1 (0.40) | CRHR1 | |
| SCHEMBL5844815 | 0.77 | ALDH1A1 (0.41) | CRHR1 | |
| SCHEMBL27489799 | 0.75 | CRHR1 (0.36) | CRHR1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6833378-B2 | Pyridines, pyrimidines, purinones, pyrrolopyrimidinones and pyrrolopyridinones; useful in the treatment disorders including CNS and stress-related disorders. | PFIZER INC | 2004-12-21 | — | — | US | disclosed |
| EP-1263732-A1 | CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | Pfizer Products Inc. (US) | 2002-12-11 | — | — | EP | disclosed |
| US-20020016328-A1 | Corticotropin releasing factor antagonists | PFIZER INC. | 2002-02-07 | — | — | US | disclosed |
| WO-2001053263-A1 | CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2001-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016328-A1 | Corticotropin releasing factor antagonists | CRH, CRHR2, CRHR1 | GAA 2029/4885MAPT 2253/4885KDM4E 2820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.